Pepto-Bismol isn’t technically “banned” across all of Europe, but it is unavailable over the counter in most EU countries. The reason comes down to safety concerns about its active ingredient, bismuth subsalicylate, which triggered a serious public health crisis in France during the 1970s and led to lasting regulatory restrictions on bismuth-containing medicines throughout the continent.
The Bismuth Neurotoxicity Crisis
Between 1973 and 1980, roughly 1,000 cases of bismuth-related brain toxicity were reported in France alone, resulting in 72 deaths among 942 patients. Dozens more cases appeared in Australia, Belgium, Switzerland, and Spain. The affected patients had taken large doses of bismuth compounds over extended periods, sometimes for weeks and sometimes for decades. Symptoms included confusion, difficulty walking, tremors, and in severe cases, a full-blown toxic brain condition known as bismuth encephalopathy.
France responded by pulling most bismuth-based medications from pharmacy shelves. Other European countries followed with their own restrictions, and the cautious regulatory stance stuck. While Pepto-Bismol uses a different bismuth salt (bismuth subsalicylate) than the compounds responsible for most French cases (bismuth subnitrate and subgallate), European regulators have generally treated all bismuth salts with heightened scrutiny ever since.
The Salicylate Problem
Bismuth subsalicylate breaks down in the body to release salicylate, a compound closely related to aspirin. This creates a second layer of regulatory concern, particularly around children. Salicylates given to children during viral illnesses are linked to Reye’s syndrome, a rare but potentially fatal condition that causes swelling in the liver and brain. The American Academy of Pediatrics has noted there isn’t enough data to confidently rule out this risk in children taking bismuth subsalicylate, which is one reason the drug is not recommended for pediatric use even in countries where it’s sold.
European regulators tend to be more conservative than their American counterparts when it comes to over-the-counter access to salicylate-containing products. The combination of bismuth toxicity history and salicylate risk made bismuth subsalicylate a hard sell for OTC approval in most EU member states.
It’s Not Banned Everywhere in Europe
The situation is more nuanced than a blanket ban. In the United Kingdom, Pepto-Bismol holds a marketing authorization from the Medicines and Healthcare products Regulatory Agency and is available as an oral suspension. The UK, now outside the EU, has its own regulatory framework, and bismuth subsalicylate at the concentrations found in Pepto-Bismol passed its safety review.
Other bismuth compounds are also approved within the EU itself. A prescription combination product called Pylera, which contains bismuth subcitrate potassium alongside two antibiotics, is authorized across multiple European member states for treating stomach ulcers caused by H. pylori bacteria. The key difference is that Pylera is a short-course prescription medication taken under medical supervision, not something you grab off a pharmacy shelf for an upset stomach. European regulators are comfortable with bismuth when a doctor controls the dose and duration.
What Europeans Use Instead
If you’re traveling in Europe and looking for something to settle your stomach or stop diarrhea, you’ll find different products on pharmacy shelves. Loperamide (sold as Imodium in many countries) is the most widely available OTC option for diarrhea. For indigestion and heartburn, antacids containing calcium carbonate, magnesium, or aluminum are standard. Proton pump inhibitors like omeprazole are also available without a prescription in several EU countries.
None of these are direct replacements for Pepto-Bismol’s particular combination of anti-diarrheal, antacid, and mild anti-inflammatory effects. But they cover the same symptoms individually, and European pharmacists can recommend the right option for what you’re experiencing.
Why the U.S. and Europe Disagree
The split comes down to how each regulatory system weighs risk. The FDA considers bismuth subsalicylate safe at recommended doses for adults and has kept it available OTC since the 1900s. Reported cases of bismuth toxicity in the U.S. have involved chronic overuse or high doses well beyond what the label recommends, with blood levels of bismuth hundreds of times above normal thresholds.
European regulators, shaped by the French crisis, take a more precautionary approach. Even though the French cases involved different bismuth salts taken in much higher quantities over longer periods, the episode left a lasting institutional wariness. The EU’s default position is that if safer alternatives exist for common symptoms like indigestion and diarrhea, there’s no compelling reason to approve a product that carries even a small risk of neurotoxicity with misuse. That philosophy, rather than any single dramatic safety finding about Pepto-Bismol specifically, is what keeps it off most European shelves.